No Data
Saisheng Pharmaceutical: 2024 Annual Report Summary
Saisheng Pharmaceutical: 2024 Annual Report
Beijing Science Sun Pharmaceutical (300485.SZ) announces its performance for the year 2024, shifting from profit to a loss of 68.8531 million yuan.
Beijing Science Sun Pharmaceutical (300485.SZ) released its annual report for 2024, with the company's revenue amounting to 0.416 billion yuan...
Beijing Science Sun Pharmaceutical (300485.SZ): The application for the domestic production registration and listing license of Dapagliflozin Tablets has been accepted.
Gelonghui, on March 17, reports that Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary, Peking Saer Bio-Pharmaceutical Co., Ltd. (referred to as "Saer Bio"), recently received the "Acceptance Notice" from the National Medical Products Administration for the drug registration application for the domestic production of Dapagliflozin tablets. Dapagliflozin is a new oral hypoglycemic agent, first developed by Bristol-Myers Squibb, which later licensed the intellectual property and global production and sales rights to AstraZeneca. In 2012, Dapagliflozin was approved by the European EMA for the treatment of type 2 diabetes, making it the first SGLT-2 class drug approved globally.
Beijing Science Sun Pharmaceutical (300485.SZ) subsidiary has received the approval notification for a drug clinical trial.
Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. has received the national pharmaceutical supervision...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.